Animalcare GroupLSE:ANCR +0.45%79 EBITDA Margin % is 22.94% as of Dec. 2025, which is 44% above its 10-year median of 15.92. GuruFocus rates LSE:ANCR with a GF Score™ of 79/100 and a GF Value™ of £2.56 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 954 Drug Manufacturers companies, Animalcare Group ranks better than 73.48% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Animalcare Group's EBITDA for the
six
months ended in Dec. 2025 was £10.40 Mil. Animalcare Group's Revenue for the
six
months ended in Dec. 2025 was £45.35 Mil. Therefore, Animalcare Group's EBITDA margin for the quarter that ended in Dec. 2025 was 22.94%.
Animalcare Group (LSE:ANCR) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Animalcare Group EBITDA Margin % Related Terms
Animalcare Group EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Animalcare Group's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:ANCR vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Animalcare Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Animalcare Group EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Animalcare Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Animalcare Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Animalcare Group (LSE:ANCR) has a EBITDA Margin % of 22.94% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Animalcare Group and its competitors. This is 44% above median its historical median of 15.92. Over the past decade, Animalcare Group's EBITDA Margin % has ranged from 11.84 to 24.66. According to the industry distribution chart, Animalcare Group ranks #253 out of 954 companies in the Drug Manufacturers industry, placing it in the top 26.5%.
Is Animalcare Group's EBITDA Margin % too high?
Animalcare Group's current EBITDA Margin % of 22.94% is 44% above median its 10-year median of 15.92. Over the past 10 years, this metric has ranged from a low of 11.84 to a high of 24.66. The Drug Manufacturers industry median EBITDA Margin % is 12.52. Animalcare Group's value of 22.94% is 83.3% above this industry median. Based on the distribution chart, Animalcare Group ranks #253 out of 954 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Animalcare Group has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Animalcare Group's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Animalcare Group ranks #253 out of 954 companies for EBITDA Margin %. This puts Animalcare Group in the upper half of its industry. The industry median EBITDA Margin % is 12.52. Animalcare Group's value of 22.94% is 83.3% above this benchmark. Historically, Animalcare Group's own EBITDA Margin % has ranged from 11.84 to 24.66 over the past decade. While the company's 10-year median is 15.92 vs. the industry median of 12.52, Animalcare Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.52, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Animalcare Group's current EBITDA Margin % of 22.94% is 83.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Animalcare Group and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Animalcare Group's current EBITDA Margin % is 22.94%, which is 44% above median its own 10-year median of 15.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Animalcare Group stock overvalued right now?
Based on GuruFocus' analysis, Animalcare Group (LSE:ANCR) is currently considered Modestly Overvalued. The stock's GF Value™ is £2.56, compared to a current price of £3.34 — trading 30.3% above its estimated fair value. The current EBITDA Margin % is 22.94%, which is 44% above median its 10-year median of 15.92 and 83.3% above the Drug Manufacturers industry median of 12.52. Animalcare Group's overall GF Score™ is 79/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Animalcare Group (LSE:ANCR), the current EBITDA Margin % is 22.94% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Animalcare Group (LSE:ANCR) Overvalued in 2026?
Based on GuruFocus' analysis, Animalcare Group stock appears to be overvalued.
The current stock price of £3.34 is trading 30.3% above its estimated GF Value™ of £2.56.
GuruFocus considers Animalcare Group to be Modestly Overvalued.
Key valuation signals for LSE:ANCR:
EBITDA Margin %: 22.94% (44% above median its 10-year median of 15.92)
GF Value™: £2.56 vs. price of £3.34 (30.3% above fair value)
Industry Position: 83.3% above the Drug Manufacturers median (#253 of 954)
No single metric tells the full story. See the LSE:ANCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Animalcare Group PLC is active in the healthcare division in the United Kingdom. It is a generic veterinary medicines company. The company mainly caters to veterinary professionals in the treatment of companion animals through a product line comprised of licensed veterinary medicines and companion animal identification products and services. The company operates in Animalcare Europe and Randlab segment. The company derives maximum revenue from the Animalcare Europe segment engaged in development and sale of veterinary pharmaceutical products in Europe and the European International Partners network. Geographically, the company derives maximum revenue from Europe region, followed by Asia-Pacific and other regions.
79GF Score
Get the complete analysis for LSE:ANCR
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:ANCR has been successfully added to your 
